000281642 001__ 281642
000281642 005__ 20251103102758.0
000281642 0247_ $$2doi$$a10.1212/NXI.0000000000200491
000281642 0247_ $$2pmid$$apmid:41061183
000281642 037__ $$aDZNE-2025-01160
000281642 041__ $$aEnglish
000281642 082__ $$a610
000281642 1001_ $$00000-0003-0631-8506$$aAbu-Rumeileh, Samir$$b0
000281642 245__ $$aCSF Beta-Synuclein, SNAP-25, and Neurogranin in Infectious and Autoimmune Inflammatory Neurologic Diseases.
000281642 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2025
000281642 3367_ $$2DRIVER$$aarticle
000281642 3367_ $$2DataCite$$aOutput Types/Journal article
000281642 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762161596_20025
000281642 3367_ $$2BibTeX$$aARTICLE
000281642 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281642 3367_ $$00$$2EndNote$$aJournal Article
000281642 520__ $$aBeta-synuclein (beta-syn), synaptosomal-associated protein 25 (SNAP-25), and neurogranin are CSF biomarkers of synaptic damage, which have been poorly investigated in non-neurodegenerative neurologic diseases. In this study, we examined the diagnostic and prognostic role of these markers compared with the neuroaxonal damage marker neurofilament light chain protein (NfL) in infectious and autoimmune inflammatory neurologic diseases (IINDs and AINDs).This cohort study included CSF samples from patients with different etiologies of IIND (varicella-zoster virus, herpes simplex virus, tick-borne meningoencephalitis, bacterial meningitis/(meningo)encephalitis, neuroborreliosis, or other/unknown etiology) or AIND (autoimmune encephalitis or other etiology) as well as controls.A total of 123 patients with IINDs (mean age 55.23 ± 18.04 years, 43.2% female), 22 with AINDs (age 60.41 ± 16.03 years, 81.8% female), and 95 controls (age 52.39 ± 17.94 years, 56.9% female) were enrolled. Compared with the control group, participants with IINDs and AINDs showed higher concentrations of beta-syn (p < 0.001 and p = 0.038, respectively), neurogranin (p = 0.039 and p = 0.002, respectively), and NfL (p < 0.001 and p = 0.001, respectively), with no differences between the 2 latter groups. Overall, synaptic markers and NfL demonstrated poor-to-moderate diagnostic accuracy in discriminating between diagnostic groups (area under the curve 0.366-0.809). All synaptic biomarkers were elevated in participants with IINDs presenting with altered mental status (beta-syn, p < 0.001; SNAP-25, p = 0.002; and neurogranin, p = 0.008), seizures (beta-syn, p = 0.013; SNAP-25, p = 0.005; and neurogranin, p = 0.004), and inflammatory changes on neuroimaging (beta-syn, p = 0.016; SNAP-25, p = 0.029; and neurogranin, p = 0.007). Participants with AINDs requiring intensive care showed higher levels of beta-syn (p = 0.033) and NfL (p = 0.002). Participants with IINDs with a poor functional status (modified Rankin Scale [mRS] scores of 3-6) exhibited higher concentrations of beta-syn (p < 0.001), SNAP-25 (p = 0.022), neurogranin (p = 0.004), and NfL (p < 0.001) compared with those with mRS scores of 0-2. Accordingly, higher levels of synaptic markers were associated with poorer short-term outcomes in patients with IINDs, but not in those with AINDs.Elevated CSF levels of beta-syn, neurogranin, and NfL may suggest a common pattern of synaptic and neuroaxonal damage in both IINDs and AINDs. Although these biomarkers have limited value in distinguishing between different diseases, they are associated with clinical severity and with short-term outcome, particularly in patients with IINDs.
000281642 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281642 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281642 650_7 $$0132654-77-4$$2NLM Chemicals$$aNeurogranin
000281642 650_7 $$2NLM Chemicals$$aBiomarkers
000281642 650_7 $$2NLM Chemicals$$aSynaptosomal-Associated Protein 25
000281642 650_7 $$2NLM Chemicals$$aSNAP25 protein, human
000281642 650_7 $$2NLM Chemicals$$aSNCA protein, human
000281642 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000281642 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000281642 650_7 $$2NLM Chemicals$$aneurofilament protein L
000281642 650_2 $$2MeSH$$aHumans
000281642 650_2 $$2MeSH$$aFemale
000281642 650_2 $$2MeSH$$aMale
000281642 650_2 $$2MeSH$$aMiddle Aged
000281642 650_2 $$2MeSH$$aNeurogranin: cerebrospinal fluid
000281642 650_2 $$2MeSH$$aAged
000281642 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000281642 650_2 $$2MeSH$$aAdult
000281642 650_2 $$2MeSH$$aSynaptosomal-Associated Protein 25: cerebrospinal fluid
000281642 650_2 $$2MeSH$$aAutoimmune Diseases of the Nervous System: cerebrospinal fluid
000281642 650_2 $$2MeSH$$aAutoimmune Diseases of the Nervous System: diagnosis
000281642 650_2 $$2MeSH$$aCohort Studies
000281642 650_2 $$2MeSH$$aNeuroinflammatory Diseases: cerebrospinal fluid
000281642 650_2 $$2MeSH$$aNeuroinflammatory Diseases: diagnosis
000281642 650_2 $$2MeSH$$aalpha-Synuclein: cerebrospinal fluid
000281642 650_2 $$2MeSH$$aEncephalitis: cerebrospinal fluid
000281642 650_2 $$2MeSH$$aEncephalitis: diagnosis
000281642 650_2 $$2MeSH$$aNeurofilament Proteins: cerebrospinal fluid
000281642 7001_ $$aErhart, Deborah K$$b1
000281642 7001_ $$00000-0003-1328-3620$$aBarba, Lorenzo$$b2
000281642 7001_ $$00000-0002-8609-5674$$aKonen, Franz Felix$$b3
000281642 7001_ $$aStapf, Caroline$$b4
000281642 7001_ $$00000-0002-2737-7495$$aSenel, Makbule$$b5
000281642 7001_ $$00000-0002-1402-5415$$aHudasch, Dominica$$b6
000281642 7001_ $$00000-0001-6697-6522$$aSteinacker, Petra$$b7
000281642 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b8$$udzne
000281642 7001_ $$aWeise, Christopher M$$b9
000281642 7001_ $$00000-0001-5963-7426$$aTicozzi, Nicola$$b10
000281642 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b11
000281642 7001_ $$00000-0002-3977-6995$$aVerde, Federico$$b12
000281642 7001_ $$00000-0002-8077-481X$$aSühs, Kurt-Wolfram$$b13
000281642 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b14$$udzne
000281642 7001_ $$00000-0003-4273-4267$$aOtto, Markus$$b15
000281642 773__ $$0PERI:(DE-600)2767740-0$$a10.1212/NXI.0000000000200491$$gVol. 12, no. 6, p. e200491$$n6$$pe200491$$tNeurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology$$v12$$x2332-7812$$y2025
000281642 8564_ $$uhttps://pub.dzne.de/record/281642/files/DZNE-2025-01160.pdf$$yOpenAccess
000281642 8564_ $$uhttps://pub.dzne.de/record/281642/files/DZNE-2025-01160.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281642 909CO $$ooai:pub.dzne.de:281642$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000281642 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000281642 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000281642 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002007$$aExternal Institute$$b14$$kExtern
000281642 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281642 9141_ $$y2025
000281642 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000281642 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000281642 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-13T18:57:06Z
000281642 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-13T18:57:06Z
000281642 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281642 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-02-13T18:57:06Z
000281642 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000281642 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000281642 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000281642 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x1
000281642 980__ $$ajournal
000281642 980__ $$aVDB
000281642 980__ $$aUNRESTRICTED
000281642 980__ $$aI:(DE-2719)5000073
000281642 980__ $$aI:(DE-2719)5000077
000281642 9801_ $$aFullTexts